Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP859425.RAAW_wa_538sdKzeFPc6Q39MbhPYEyMzAI5IB5VGhPkbk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP859425.RAAW_wa_538sdKzeFPc6Q39MbhPYEyMzAI5IB5VGhPkbk130_assertion type Assertion NP859425.RAAW_wa_538sdKzeFPc6Q39MbhPYEyMzAI5IB5VGhPkbk130_head.
- NP859425.RAAW_wa_538sdKzeFPc6Q39MbhPYEyMzAI5IB5VGhPkbk130_assertion description "[A number of targeted approaches to TNBC are undergoing clinical evaluation, including the use of agents with poly(ADP-ribose) polymerase inhibitory properties such as iniparib (the United States Adopted Name for the investigational agent BSI-201), olaparib (AZD2281), and veliparib (ABT-888), antiangiogenic agents such as bevacizumab and sunitinib, and epidermal growth factor receptor blockers such as cetuximab and erlotinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP859425.RAAW_wa_538sdKzeFPc6Q39MbhPYEyMzAI5IB5VGhPkbk130_provenance.
- NP859425.RAAW_wa_538sdKzeFPc6Q39MbhPYEyMzAI5IB5VGhPkbk130_assertion evidence source_evidence_literature NP859425.RAAW_wa_538sdKzeFPc6Q39MbhPYEyMzAI5IB5VGhPkbk130_provenance.
- NP859425.RAAW_wa_538sdKzeFPc6Q39MbhPYEyMzAI5IB5VGhPkbk130_assertion SIO_000772 21161370 NP859425.RAAW_wa_538sdKzeFPc6Q39MbhPYEyMzAI5IB5VGhPkbk130_provenance.
- NP859425.RAAW_wa_538sdKzeFPc6Q39MbhPYEyMzAI5IB5VGhPkbk130_assertion wasDerivedFrom befree-2016 NP859425.RAAW_wa_538sdKzeFPc6Q39MbhPYEyMzAI5IB5VGhPkbk130_provenance.
- NP859425.RAAW_wa_538sdKzeFPc6Q39MbhPYEyMzAI5IB5VGhPkbk130_assertion wasGeneratedBy ECO_0000203 NP859425.RAAW_wa_538sdKzeFPc6Q39MbhPYEyMzAI5IB5VGhPkbk130_provenance.